



Aptar's Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™

Crystal Lake, Illinois, January 12, 2026 —AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today shared an overview of its growing portfolio of eye care solutions including its new technology, Beat the Blink™, a delivery system designed to improve dosing precision and enhance patient experience by “beating the blink” reflex, currently part of an exclusive partnership with Bausch and Lomb.

Avoiding preservatives in eye care formulations may help to make treatments more tolerable. As such, preservative-free multidose systems (PFMD) are gaining more importance for topical ophthalmic treatment applications. Whether these treatments are for prescribed drugs or over-the-counter drugstore products, the microbiological integrity of the PFMD is crucial. Aptar's portfolio of market-leading ophthalmic delivery systems is designed to meet the key needs of patients for safe, precise eye care delivery. With over 500 market references, Aptar's innovative and growing portfolio of eye care solutions is a go-to platform for ophthalmic drug delivery. This portfolio includes:

Beat the Blink™

Beat the Blink is a new eye care delivery system designed to improve dosing precision and enhance patient experience by “beating the blink” reflex. Aptar's technology aims to address an unmet need: improving consumer experience by eliminating the need to tilt the head, which may cause targeting errors leading to insufficient administration of eye drops.



Key features include horizontal drop delivery and formula protection through a tip seal for preservative-free formulations. Additionally, the design of Beat the Blink is intended to ensure compliance with regulatory and quality requirements for ophthalmic solutions, incorporating a child-resistant concept, new bottle and ventilation design, microbial safety measures and intended compatibility with a wide range of eye care formulations. This technology is currently part of an exclusive partnership with Bausch and Lomb, a leading global eye care company, and commercial availability is expected to follow the completion of development and industrialization (estimated 24 to 36 months).

Ophthalmic Squeeze Dispenser

Aptar's [Ophthalmic Squeeze Dispenser \(OSD\)](#) is a leading preservative-free multidose eye dropper worldwide. The Ophthalmic Squeeze Dispenser utilizes a purely mechanical Tip-Seal technology that has been developed for use without preservatives and additives such as silver ions or surface coating. Aptar's patented Tip-Seal technology has been tested by microbial challenge procedures simulating relevant in-use scenarios (however, customer formulations will require additional testing). Aptar provides a set of data and test methods for the



Ophthalmic Squeeze Dispenser which are designed to help support pharmaceutical customers in preparing their finished product dossier.

APF Advanced Preservative Free

Aptar's [Advanced Preservative Free](#) and its Advanced Preservative Free PLUS pumps, which add dermal, oral and eye care to the preservative-free offering, constitute an innovative spray dispensing system for nasal and topical applications that provide microbiological protection and stability for sensitive formulations using purely mechanical means and granting a metal-free fluid path. Aptar's [APF Futurity™](#) recyclable system represents the first metal free, all plastic multidose nasal spray system rated as highly recyclable by cyclos-HTP.



Digital Healthcare Solutions

Aptar offers a broad range of innovative [digital healthcare solutions](#) for the prevention, diagnosis and treatment of diseases, including patient monitoring and healthcare management. All of Aptar's digital healthcare solutions, including for eye care, are patient-friendly, easy-to-use, intuitive and available as fully integrated technologies or extensions.

"Our extensive R&D capabilities, new systems development and customizable solutions allow us to offer a leading range of eye care solutions designed to improve dosing precision and enhance the patient and consumer experience," said Gael Touya, President, Aptar Pharma. "Our partnership approach and suite of services help our customers meet evolving needs in eye care and navigate the challenges associated with developing both prescription and over-the-counter treatments."

About Aptar

Aptar is a global leader in drug delivery and consumer product, dispensing, dosing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

This press release contains forward-looking statements, including the anticipated benefits, development timeline and commercial availability of Beat the Blink. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as "expects," "anticipates," "believes," "estimates," "future," "potential," "continues" and other similar expressions or future or conditional verbs such as "will," "should," "would" and "could" are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: development and commercialization risks; customer adoption; regulatory requirements and compliance; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

#

Aptar Investors Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

+1 347 351 6407

Aptar Pharma Media Contact:

Carolyn Penot

carolyn.penot@aptar.com

+33 6 37 36 76 84

Aptar Media Contact:

Katie Reardon

katie.reardon@aptar.com

+1 815 479 5671